Mineralys Therapeutics, Inc. MLYS R2KR3KPHARMA
Company Overview
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.18.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +51.55% |
| 6 Months: | -25.30% |
| 3 Months: | -24.48% |
| 1 Month: | -22.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MLYS Mineralys Therapeutics, Inc. R2KR3KPHARMA | 20.55 | -4.89 | $1.81B | 0.00% | -26.38% | -80.88% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -7.57M | -6.48M | -7.42M | -14.94M | -15.73M | -26.27M | -35.36M | -45.17M | -60.11M | -44.45M | -46.75M | -41.13M | -45.34M |
| Net Income | -7.57M | -6.48M | -6.68M | -12.61M | -12.14M | -22.76M | -31.51M | -41.01M | -56.34M | -42.21M | -43.27M | -36.93M | -39.34M |
| Diluted EPS | -1.48 | -1.26 | -1.29 | -0.51 | -0.31 | -0.57 | -0.70 | -0.83 | -1.13 | -0.79 | -0.66 | -0.52 | -0.47 |
| R&D Expense | 6.78M | 5.59M | 6.06M | 12.29M | 11.88M | 22.50M | 30.75M | 39.27M | 53.98M | 37.88M | 38.28M | 31.45M | 24.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 31.48M | 84.66M | 192.40M | 170.60M |
| Operating Income | - | -31.48M | -84.66M | -192.40M | -170.60M |
| EBITDA | - | -31.48M | -84.66M | -192.36M | -170.54M |
| Interest Expense | 27.00K | - | - | - | - |
| Pretax Income | - | -29.80M | -71.90M | -177.81M | -154.65M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -29.80M | -71.90M | -177.81M | -154.65M |
| Diluted EPS | - | -0.76 | -1.99 | -3.66 | -2.29 |
| R&D Expense | - | 26.25M | 70.36M | 168.58M | 132.01M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 114.44M | 251.64M | 205.90M | 661.81M |
| Total Equity | -22.93M | -52.27M | 241.15M | 191.26M | 646.69M |
| Cash & Equivalents | - | 87.70M | 49.30M | 114.09M | 172.92M |
| Current Liabilities | - | 8.07M | 10.48M | 14.65M | 15.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -29.22M | -81.17M | -166.31M | -142.42M |
| Investing Cash Flow | -21.76M | -160.47M | 114.96M | -389.75M |
| Financing Cash Flow | 128.02M | 203.25M | 116.14M | 591.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 57.0% | -29.8% | -93.0% | -23.9% |
| ROCE % | - | -29.6% | -35.1% | -100.6% | -26.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Catalys Pacific, LLC | 8.94% | 7.90M | $184.71M |
| 2 | RA Capital Management, L.P. | 8.70% | 7.69M | $179.78M |
| 3 | Blackrock Inc. | 6.66% | 5.89M | $137.58M |
| 4 | Samsara BioCapital, LLC | 6.64% | 5.87M | $137.21M |
| 5 | FMR, LLC | 5.10% | 4.51M | $105.44M |
| 6 | State Street Corporation | 4.68% | 4.14M | $96.79M |
| 7 | Deerfield Management Company, L.P | 4.48% | 3.96M | $92.50M |
| 8 | Vanguard Capital Management LLC | 3.12% | 2.76M | $64.43M |
| 9 | Laurion Capital Management, LP | 2.83% | 2.51M | $58.57M |
| 10 | Price (T.Rowe) Associates Inc | 2.56% | 2.26M | $52.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLYS
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPSDZPT0h6QTJfZnRCR0RBRTBWUE93elUzUlZGVmdqUXZkb19oRnpqWEUwckVvUXFWNWw0V0FxWlNadTkxQkpUZEY3NFFKQmlodkZlbDZPRWtfQ2czZklHWDF1QkJ1M0JFYThwVUMyZHlYT1JCTldUNmtMc0FqLUo2aTdzem5aSm5HRGRqMU…
Why (MLYS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQYTludFlKSUtrNUt2Sm1LSDFtNWlwRmtrVTAxMHJJN2Q1RlJZS0p1ZEtvZlh6ZGVJWmhXdnpCZ1dDNnRXd0NBMHRYWU9fVDNVZWFnVGdfZWJnWVAxZmVrWmV2UmVMUVRkY2JGQU1za2s0dmU1dnlOcU14ei15eHY3cVpqYU44dl9XemZBMV…
Mineralys Therapeutics CEO Jon Congleton sells $1.9m MLYS stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPTDBsVjdpLWRIZjAxaUs5ZUFHaGZCU3dlQTJKX29EQWFtdXJMdHY1c1Rad2JlVmRwWEhlcDZ5aklzOVl2RDVmV05OVHRZN0piclUxc3RoZzZFNGFrc2hGaW9ycVg2eVp5WElId3hDN2lKdWJRVUhncm9EMDI0TzNxTDd4M1E5VDNhVktVUT…
A blood pressure drug cut urine protein 52% vs. placebo among people with kidney disease and protein in their urine. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQSm5aSlBzN0RVVTlaUjVXYjctV2RiQlJMNjlGRDc1YWlLU2Iyb0dRVmdjbEx3Nll6dnlVNHhCY1JvdGdOQVFtalpkMEhJN0N6U19iZFdvc0lpUFFaN3o0cTd0SGl4X2JmdlBqeWthUmh5d3pPVUdyY2d1Y3lSMFF2bC1LeEhkVE1PdC15dT…
Mineralys Therapeutics (MLYS) Stock Dropped, So What Is Driving Attention Now? - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNb2ZZam1ZWWpMdVdULVQ1TlFGRkpxdVV6X2thNDhuamRTSVEycVpJN3MwTHB5S1dxa1pxSjBuNXhCbWUxX0NrbzZueUVaQVRBOC1PVjhTaTdWcEFJTDJrNjNZZFdsWmstYW56ckI1V2FTSDRZZk9WVzZuejR3WEJNMzQ1WnluTTFOZ2xUcj…
MLYS Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFB1Vkp6cURBMGJzc1dFWG5MOTdYUV9RMFFfM1l1ZUZBQ25oWEJ0SWt6TzV1U1ZRWFFETW13NmpqcDdoLTRtMnN4WHpEeUFKTmhqdjJINy1OSmFONGpuOFpkRVNaRl9jeU9IeUF2SGkyV2NFV3l2WkIyOEt3?oc=5" target="_blank">MLY…
MLYS — Frequently Asked Questions
What is the current share price of Mineralys Therapeutics, Inc. (MLYS)?
As of 2026-10-23 16:27 PDT, Mineralys Therapeutics, Inc. (MLYS) trades at $20.55 on NasdaqGS. Its 52-week range is $13.56 to $47.33.
What is the market capitalisation of MLYS?
Mineralys Therapeutics, Inc. (MLYS) has a market capitalisation of $1.81B on NasdaqGS.
What is the P/E ratio of MLYS?
MLYS trades at a trailing price-to-earnings (P/E) ratio of -4.89. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 4.49.
What is the return on equity (ROE) of MLYS?
MLYS has a return on equity (ROE) of -80.88%. Its return on capital employed (ROCE) is -26.38%.
Is MLYS a good stock to buy?
This page provides a data-driven analysis of Mineralys Therapeutics, Inc. (MLYS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.